Author name: Inhibitec

Inhibitec has received funding ((€3,533.45) through the Planes de Promoción Comercial program (NM25-PC-109), supported by Sociedad para el Desarrollo Regional de Cantabria (SODERCAN). This grant allowed us to cover 50% of the funding for three international activities, which are part of its strategy to increase international visibility, open new markets, and expand its network of […]

Inhibitec Antibodies has been selected for the ‘Programa Personal Técnico I+D’, supported by Sociedad para el Desarrollo Regional de Cantabria (SODERCAN), enabling us to expand our scientific team with the addition of a new R&D technician (RH25-XX-011). We sincerely appreciate SODERCAN’s continued support for Inhibitec since the early stages of our project.

Inhibitec Antibodies has been one of the startups selected in the ‘Programa Personal Tecnico I+D’ supported by Sociedad para el Desarrollo Regional de Cantabria (SODERCAN) to expand its scientific team with the addition of an R&D technician (RH23-XX-025). We greatly appreciate the support of SODERCAN for Inhibitec since the beginning of our project. https://boc.cantabria.es/boces/verAnuncioAction.do?idAnuBlob=386579

Towards a new therapy in psoriasis and psoriatic arthritis Inhibitec Anticuerpos S.L. has been selected as a recipient of the grant CPP2022-009666, supporting the development of the public–private collaborative project “Towards a new therapy in psoriasis and psoriatic arthritis”, within the framework of the Plan Estatal de Investigación Científica, Técnica y de Innovación (PEICTI) 2021–2023.

Towards a novel disruptive therapy in autoimmune disease We are thrilled to announce that Inhibitec has been selected as a recipient of the NEOTEC 2021 grant provided by CDTI (Center for Industrial Technological Development) with the support of the Ministerio de Ciencia e Innovación. This prestigious grant is designed to impulse new entrepreneurial projects that